Peter Stock, MD

Transplant surgeon

Dr. Peter Stock is a transplant surgeon who specializes in kidney, liver and pancreas transplants. He is co-director of the Pancreatic Islet Cell Transplantation Program.

In his research, Stock studies body mechanisms that lead to transplant rejection when the donor and recipient are not genetically identical. He also studies chimerism (a therapy to prevent transplant rejection that uses the donor's bone marrow cells) and pancreatic islet cell transplantation (a procedure that can allow people with type 1 diabetes to discontinue insulin therapy).

Stock received his medical training at the University of Minnesota, completing a surgical residency before coming to UCSF for a transplant fellowship. He joined the UCSF faculty in 1992.

Stock is an active teacher and supervises surgical residents and fellows. He is a member of numerous professional and honorary societies.

Clinics

Kidney Transplant Program
1825 Fourth St., Sixth Floor
San Francisco, CA 94158
Phone: (415) 353-8377
Toll-free: (800) 482-7389

Liver Transplant Program
1825 Fourth St., Sixth Floor
San Francisco, CA 94158
Phone: (415) 476-5892
Fax: (415) 476-1343

Conditions & Treatments

More about Peter Stock

Education

University of Illinois School of Medicine 1982

Residencies

University of Minnesota Medical Center, General Surgery 1990

Fellowships

UCSF Medical Center, Transplant Surgery 1992

Selected Research and Publications

  1. Mock C, Debas H, Balch CM, Brennan M, Buyske J, Cusack J, DeMeester S, Herndon D, Le Holterman AX, Jaffe B, Kandil E, Kauffman G, Mazariegos G, Merchant N, Numann P, Oleynikov D, Olutoye O, O'Neill J, Shackford S, Stock P, Tarpley JL, Tuttle T, Wolf S, Wren SM, Yang GP. Global Surgery: Effective Involvement of US Academic Surgery: Report of the American Surgical Association Working Group on Global Surgery. Ann Surg. 2018 Jul 12.
  2. Yamanaga S, Rosario A, Fernandez D, Kobayashi T, Tavakol M, Stock PG, Kang SM. Inferior long-term graft survival after end-to-side reconstruction for two renal arteries in living donor renal transplantation. PLoS One. 2018; 13(7):e0199629.
  3. Durand CM, Halpern SE, Bowring MG, Bismut GA, Kusemiju OT, Doby B, Fernandez RE, Kirby CS, Ostrander D, Stock PG, Mehta SG, Turgeon NA, Wojciechowski D, Huprikar S, Florman S, Ottmann S, Desai NM, Cameron A, Massie AB, Tobian AAR, Redd AD, Segev DL. Organs from Deceased Donors with False-Positive HIV Screening Tests: An Unexpected Benefit of the HOPE Act. Am J Transplant. 2018 Jun 27.
  4. Sneddon JB, Tang Q, Stock P, Bluestone JA, Roy S, Desai T, Hebrok M. Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges. Cell Stem Cell. 2018 Jun 01; 22(6):810-823.
  5. Rickels MR, Stock PG, de Koning EJP, Piemonti L, Pratschke J, Alejandro R, Bellin MD, Berney T, Choudhary P, Johnson PR, Kandaswamy R, Kay TWH, Keymeulen B, Kudva YC, Latres E, Langer RM, Lehmann R, Ludwig B, Markmann JF, Marinac M, Odorico JS, Pattou F, Senior PA, Shaw JAM, Vantyghem MC, White S. Defining outcomes for ß-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop. Transpl Int. 2018 Apr; 31(4):343-352.
  6. Rickels MR, Stock PG, de Koning EJP, Piemonti L, Pratschke J, Alejandro R, Bellin MD, Berney T, Choudhary P, Johnson PR, Kandaswamy R, Kay TWH, Keymeulen B, Kudva YC, Latres E, Langer RM, Lehmann R, Ludwig B, Markmann JF, Marinac M, Odorico JS, Pattou F, Senior PA, Shaw JAM, Vantyghem MC, White S. Defining Outcomes for ß-Cell Replacement Therapy in the Treatment of Diabetes: a Consensus Report on the Igls Criteria from the IPITA/EPITA Opinion Leaders Workshop. Transplantation. 2018 Mar 09.
  7. Piemonti L, de Koning EJP, Berney T, Odorico JS, Markmann JF, Stock PG, Rickels MR. Defining outcomes for beta cell replacement therapy: a work in progress. Diabetologia. 2018 Mar 06.
  8. Schuetz C, Anazawa T, Cross SE, Labriola L, Meier RPH, Redfield RR, Scholz H, Stock PG, Zammit NW. ß Cell Replacement Therapy: The Next 10 Years. Transplantation. 2018 Feb; 102(2):215-229.
  9. Stock PG. Strengths and weaknesses of using SRTR data to shape the management of the HIV-infected kidney transplant recipient. Am J Transplant. 2017 Dec; 17(12):3001-3002.
  10. O'Connell PJ, Kuypers DR, Mannon RB, Abecassis M, Chadban SJ, Gill JS, Murphy B, Nickerson PW, Schold JD, Stock PG, Seron D, Alloway RR, Bromberg JS, Budde K, Jordan SC, Legendre C, Lefaucheur C, Sarwall M, Segev DL, Stegall MD, Tullius SG, Wong G, Woodle ES, Ascher N, Morris RE. Clinical Trials for Immunosuppression in Transplantation: The Case for Reform and Change in Direction. Transplantation. 2017 07; 101(7):1527-1534.
  11. Ricordi C, Goldstein JS, Balamurugan AN, Szot GL, Kin T, Liu C, Czarniecki CW, Barbaro B, Bridges ND, Cano J, Clarke WR, Eggerman TL, Hunsicker LG, Kaufman DB, Khan A, Lafontant DE, Linetsky E, Luo X, Markmann JF, Naji A, Korsgren O, Oberholzer J, Turgeon NA, Brandhorst D, Friberg AS, Lei J, Wang LJ, Wilhelm JJ, Willits J, Zhang X, Hering BJ, Posselt AM, Stock PG, Shapiro AMJ. Erratum. National Institutes of Health-Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities. Diabetes 2016;65:3418-3428. Diabetes. 2017 09; 66(9):2531.
  12. Ragni MV, Humar A, Stock PG, Blumberg EA, Eghtesad B, Fung JJ, Stosor V, Nissen N, Wong MT, Sherman KE, Stablein DM, Barin B. Hemophilia Liver Transplantation Observational Study. Liver Transpl. 2017 06; 23(6):762-768.
  13. Rogers RL, Stock PG. Canadian Laws Are on Target-But Is the Transplant Community? Transplantation. 2017 04; 101(4):682-683.
  14. Chandran S, Stock PG. Opportunities and Challenges for Kidney Donation from and to HIV-Positive Individuals. Clin J Am Soc Nephrol. 2017 03 07; 12(3):385-387.
  15. Roll GR, Stock PG. Strategies to improve outcomes for hepatitis C virus/human immunodeficiency virus coinfected liver transplant candidates. Liver Transpl. 2016 09; 22(9):1181-2.
  16. Stegall MD, Stock PG, Andreoni K, Friedewald JJ, Leichtman AB. Why do we have the kidney allocation system we have today? A history of the 2014 kidney allocation system. Hum Immunol. 2017 Jan; 78(1):4-8.
  17. Campos-Varela I, Dodge JL, Stock PG, Terrault NA. Key donor factors associated with graft loss among liver transplant recipients with human immunodeficiency virus. Clin Transplant. 2016 09; 30(9):1140-5.
  18. Wisel SA, Braun HJ, Stock PG. Current outcomes in islet versus solid organ pancreas transplant for ß-cell replacement in type 1 diabetes. Curr Opin Organ Transplant. 2016 Aug; 21(4):399-404.
  19. Ricordi C, Goldstein JS, Balamurugan AN, Szot GL, Kin T, Liu C, Czarniecki CW, Barbaro B, Bridges ND, Cano J, Clarke WR, Eggerman TL, Hunsicker LG, Kaufman DB, Khan A, Lafontant DE, Linetsky E, Luo X, Markmann JF, Naji A, Korsgren O, Oberholzer J, Turgeon NA, Brandhorst D, Chen X, Friberg AS, Lei J, Wang LJ, Wilhelm JJ, Willits J, Zhang X, Hering BJ, Posselt AM, Stock PG, Shapiro AM, Chen X. National Institutes of Health-Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities. Diabetes. 2016 11; 65(11):3418-3428.
  20. Markmann JF, Bartlett ST, Johnson P, Korsgren O, Hering BJ, Scharp D, Kay TW, Bromberg J, Odorico JS, Weir GC, Bridges N, Kandaswamy R, Stock P, Friend P, Gotoh M, Cooper DK, Park CG, O'Connell PJ, Stabler C, Matsumoto S, Ludwig B, Choudhary P, Khovatchev B, Rickels MR, Sykes M, Wood K, Kraemer K, Hwa A, Stanley E, Ricordi C, Zimmerman M, Greenstein J, Montanya E, Otonkoski T. Executive Summary of IPITA-TTS Opinion Leaders Report on the Future of ß-Cell Replacement. Transplantation. 2016 Jul; 100(7):e25-31.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.